IFP Advisors Inc Lowers Stake in Bristol-Myers Squibb Co (BMY)
IFP Advisors Inc decreased its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 30.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,633 shares of the biopharmaceutical company’s stock after selling 25,068 shares during the period. IFP Advisors Inc’s holdings in Bristol-Myers Squibb were worth $3,470,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Field & Main Bank acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $887,000. Fisher Asset Management LLC boosted its holdings in Bristol-Myers Squibb by 15.4% during the fourth quarter. Fisher Asset Management LLC now owns 582,213 shares of the biopharmaceutical company’s stock worth $35,678,000 after purchasing an additional 77,720 shares during the last quarter. WoodTrust Financial Corp acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $498,000. Comprehensive Portfolio Management LLC boosted its holdings in Bristol-Myers Squibb by 280.6% during the fourth quarter. Comprehensive Portfolio Management LLC now owns 18,325 shares of the biopharmaceutical company’s stock worth $1,123,000 after purchasing an additional 13,510 shares during the last quarter. Finally, Livingston Group Asset Management CO operating as Southport Capital Management boosted its holdings in Bristol-Myers Squibb by 79.5% during the fourth quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 12,449 shares of the biopharmaceutical company’s stock worth $763,000 after purchasing an additional 5,512 shares during the last quarter. 69.82% of the stock is owned by institutional investors.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $65.94 on Friday. The company has a market cap of $108,615.74, a price-to-earnings ratio of 22.10, a price-to-earnings-growth ratio of 2.07 and a beta of 1.09. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05.
The business also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.43%. The ex-dividend date was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 271.19%.
Several research analysts recently commented on BMY shares. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Vetr cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price for the company. in a report on Thursday, December 28th. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Finally, BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $66.18.
In related news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the purchase, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “IFP Advisors Inc Lowers Stake in Bristol-Myers Squibb Co (BMY)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/02/23/ifp-advisors-inc-lowers-stake-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.